|
|
Number of case |
Age |
Sex | Diagnosis | Important findings |
Time from first diagnosis to relapse |
Time from second diagnosis to relapse |
Criteria for lineage switching |
Clinical outcome |
References |
| 1st diagnosis | 2nd diagnosis at relapse | 3rd diagnosis at second relapse | 1st diagnosis | 2nd diagnosis at relapse | 3rd diagnosis at second relapse |
|
| 1 | Neonate | F | ALL L1 | AML M5 | — | 46 XX t(1;6), t(4;11)
CD19+
CD22+
CD79a+,
MPO−
CD34−
CD117− | 46 XX t(1;6), t(4;11)
CD19−
CD22−
CD79a−
CD14+
CD33+
CD13+ | — | Day 100 after induction of chemotherapy | — | Morphologic and immunophenotypic | Died | [31] |
|
| 2 | At birth | F | AML M5 | B-ALL L1 | — | t(9;11) | Karyotype NR | — | 12 mo | — | Morphologic | Alive | [32] |
|
| 3 | At birth | F | AML M5 | B-ALL | — | t(4:11)
MPO−
CD33+
CD13+
HLA-DR+
CD14+ | t(4:11)
CD34+
CD19+
CD22+
HLADR+
CD10− | — | 18 dy | — | Morphologic and immunophenotypic | Died | [33] |
|
| 4 | 12 dy | ? | B-ALL | AML M5 | — | MLL rearrangement | MLL rearrangement | — | 7 dy | — | Morphologic | NR | [34] |
|
| 5 | 21 dy | M | Pro-B ALL | AML | — | t(4;11)
MPOX−
CD10–
CD19+
CD22+
CD34+
CD38+ | t(4;11)
CD20+
CD13+
CD14+
CD15+
CD33+
CD41+
CD61+ | — | 8 dy | — | Morphologic and immunophenotypic | Died | [35] |
|
| 6 | 3 mo | F | Pre-B cell ALL L1 | AML M4 | — | t(4;11)
PAS+
MPO−
ANBE−
CD19+
CD34+
TdT+
CD33+ | FISH with MLL signal
MPO+
ANBE+
CD2+
CD13+
CD14+
CD33+
CD41+
CD65+ | — | 2 mo | — | Morphologic and immunophenotypic | Alive after allo-HSCT | [36]
|
|
| 7 | 9 mo | M | ALL | AML M5b | — | t(11;16) | t(11;16) | — | 8 mo | — | Morphologic | Died | [37] |
|
| 8 | 15 mo | M | pro-B ALL L1 | AML M0 | — | 46 XY.
CD19+
HLA-DR+ | 46 XY t(9;11)
MPO−
CD33+
cyCD13+
cyCD33+
CD117+ | — | 76 mo | — | Morphologic, immunophenotypic and cytogenetic | Alive after allo-HSCT | [36] |
|
| 9 | 25 mo | ? | AML | ALL L1 | — | 46 XY (11q23)
PAS+
MPO− | Normal karyotype | — | 1 yr | — | Morphologic and cytogenetic | Alive | [38] |
|
| 10 | 4 yr | M | AML M5 | ALL pro-B | — | Normal karyotype
PAX 5 negative when patient was under surveillance
CD10−
CD19−
CD13+
CD14+
CD15+ | Normal karyotype
CD10+
CD19+
CD13−
CD14−
CD15− | — | 9 mo | — | Morphologic and immunophenotypic | Died | [39] |
|
| 11 | 4 yr | F | ALL L1 | AML mo | BM: ALL L1
CNS: AML mo | Normal karyotype
BM: MPO–
BM: CD13+
CD19+
D22+
CD33+
CD38+
CD34+
HLA DR+ | BM: MPO+ | Karyotype
47XX+ 18
BM: MPO–
BM: CD13−
CD19+
D22 NR
CD33+
CD38 NR
CD34 NR
HLA DR+ | 2 yr after complete remission | 1 mo | Morphologic and immunophenotypic | Died | [40] |
|
| 12 | 6 yr | M | B-lineage common cell ALL L1 | AML M4 | — | 56 XY
HLA-DR+
TdT+
CD10+
CD19+
CD22+ | 46 XY
t(8;16)
MPO+
ANBE+
HLA-DR+
CD13+
CD14+
CD33+ | — | 9 mo | — | Morphologic, immunophenotypic, and cytogenetic | Alive | [36]
|
|
| 13 | 7 yr | F | B-lineage ALL L2 | T cell ALL | AML M1 | 46, XX
MPO−
HLA-DR+,
cyIgM+
CD33.+
PAS+
NSE− | Trisomy 13
CD2+
CD5+
CD7+
CD34+
HLA-DR+
CD33+ | ANBE−.
MPO+.
CD13+,
CD33+,
CD34+
HLA-DR+ CD7+ | 14 mo | 45 dy | Morphologic, immunophenotypic and cytogenetic | Died | [36] |
|
| 14 | 8 yr | M | AML | ALL | — | Karyotype NR | Normal karyotype | — | 13 mo | — | Morphologic | Alive | [41] |
|
| 15 | 9 yr | M | ALL L1 | AML M4 | — | 56 XY | 46 XY
t(8;16) | — | 9 mo | — | Morphologic and cytogenetic | Alive | [42] |
|
| 16 | 13 yr | F | Common B-cell ALL | AML M4/M5 | — | t(12;21)
amplification of RUNX1 | Amplification of RUNX1 | — | 5 yr | — | Morphologic | Alive | [43] |
|
| 17 | 16 yr | F | T-cell ALL | AML M0 | — | 46 XX
MPO−
CD7+
CD4−
CD8−
CD1−
TdT+ | ,
XX, + X,
MPO−
CD19+
CD117+
CD33+
CD34+
CD56+ | — | 13 mo | — | Morphologic, immunophenotypic, and cytogenetic | Died | [44] |
|
| 18 | 20 yr | M | T-ALL | AML | — | 52 XY
MPO−
cytCD3+,
CD5+
CD2+
TdT+
CD7+
CD3−
CD1a−
CD10−
CD33−
CD117−
CD19−
CD13± | MPO−
CD117+
CD33+
CD13+
CD56+
TdT−
CD7−
cyCD3−
CD2−
CD5−
CD19+ | — | 21 mo | — | Morphologic and immunophenotypic | Died | [45] |
|
